The text starts here.

Non-Consolidated Semiannual Financial Report for fiscal 1997


Release Date


Apr-4-97 Eisai Ltd. launches ARICEPT (donepezil hydrochloride), a new treatment for Alzheimer's disease in the UK.
Apr-14-97 Eisai announces completion of US process research facility at Eisai Merrimack Valley Laboratories, Inc.
Apr-15-97 Eisai and Janssen Pharmaceutica announce strategic alliance for new proton pump inhibitor.
Jun-3-97 Eisai announces ground-breaking for pharmaceutical production facility inSuzhou, China.
Jun-11-97 Eisai announces the receipt of ISO 9001 certification of the design, development, production, and after-service maintenance of the Automatic Inspection Machine (AIM) for quality management and quality assurance.
Jul-15-97 Eisai's Alzheimer's treatment, ARICEPT, receives agreement for approval in 12 European countries through the mutual recognition procedure.
Jul-28-97 Eisai establishes operations in Korea.
Aug-22-97 Eisai starts operations of the KAN Research Institute, a 100 percent Eisai subsidiary, focusing on exploratory life science.
Sep-16-97 Eisai announces launch of ARICEPT (donepezil hydrochloride), a new treatment for Alzheimer's disease, in Germany.